Stem Cell Therapy Market Size, Growth, Statistics Report 2028

The stem cell therapy market is expected to grow from US$ 2,278.49 million in 2022 to US$ 6,206.89 million by 2028; it is estimated to grow at a CAGR of 18.2% from 2022 to 2028.

Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under a controlled environment in the body or a clinical laboratory, these cells divide to form more cells, called daughter cells. With the advent of modern health science, these cells have been demonstrated to play a major role in understanding the occurrence of diseases, the generation of advanced regenerative medicines, and the discovery of other drugs. Stem cells are formed in embryos, bone marrow, body fats, and umbilical cord blood, among others.

Strategic Insights

Report Coverage - Stem Cell Therapy Market

Report Coverage	Details
Market Size Value in	US$ 2,278.49 million in 2022
Market Size Value by	US$ 6,206.89 million by 2028
Growth rate	CAGR of 18.2% from 2022 to 2028
Forecast Period	2022-2028
Base Year	2022
No. of Pages	206
No. of Tables	138
No. of Charts & Figures	81
Historical data available	Yes
Segments covered	Type, Treatment, Application, and End User
Free Sample Copy Available	Get Free Sample PDF

Market Insights

Increasing Organic and Inorganic Strategies by Key Players

The key market players are taking up various organic and inorganic strategies, including mergers and acquisitions, expansions, and new product launches, to stay competitive in the market.

• In October 2022, Medipost (CEO Won-Il Oh) announced the launch of its Contract Development and Manufacturing Organization (CDMO) business for cell and gene therapy products in Korea. The company announced its new GMP facilities will house 10 cleanrooms and production facilities equipped with up-to-date equipment exclusively for CDMO.
• In December 2019, Lineage Cell Therapeutics and AgeX Therapeutics, in partnership, registered a US patent for the method of generating induced pluripotent stem cells.
• In June 2021, Allogene Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The FDA granted Fast Track designation based on the potential of ALLO-605 to address the unmet need for patients who have failed other standard multiple myeloma therapies.

Thus, many organic and inorganic strategies in the stem cell therapy market enable healthcare professionals to provide improved services.

Lucrative Regions in Stem Cell Therapy Market

Get more information on this report : Request Free Sample PDF

Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials. The FDA has also approved a few stem cell therapies involved in treating complications related to stem cell transplants. In September 2021, the US Food and Drug Administration (FDA) announced approval for "Ruxolitinib" for treating "graft-versus-host-disease" (GVHD) in patients aged 12 and above. Ruxolitinib provides a patient new hope that suffers from fatal complications associated with stem cell transplants.

Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medical conditions, including immune system diseases; blood disorders; neurological disorders; metabolic disorders; genetic disorders; and cancer types such as leukemia and lymphoma.

Type Insights

Based on type, the stem cell therapy market is segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and other stem cell therapy. The adult stem cell therapy segment held the largest market share in 2021. However, the induced pluripotent stem cell therapy segment is anticipated to register the highest CAGR during the forecast period (2022–2028).

Treatment Insights

Based on treatment, the global stem cell therapy market is bifurcated into allogeneic and autologous. The allogenic segment held the larger stem cell therapy market share in 2021. Moreover, the autologous segment is expected to grow at the highest CAGR during the forecast period.

Application Insights

In terms of application, the stem cell therapy market is divided into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications. The drug discovery and development segment held the largest market share in 2021, and it is expected to register the highest CAGR during the forecast period.

Stem Cell Therapy Market, by Type – 2021 and 2028

Get more information on this report : Request Free Sample PDF

End User Insights

Based on end user, the stem cell therapy market is bifurcated into academic & research institutes and hospitals & clinics. The academic & research institutes segment held a larger market share in 2021, and the same segment is expected to register a higher CAGR in the market during the forecast period (2022–2028).

Companies in the stem cell therapy market majorly adopt inorganic strategies such as mergers and acquisitions. A few of the recent key developments in the market are listed below.

• In June 2021, the USFDA granted Fast Track designation to ALLO-605, the next-generation AlloCAR T therapy offered by Allogene Therapeutics, Inc., targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The designation was granted on the basis of the potential of ALLO-605 to address the unmet needs of patients who didn’t respond to other standard multiple myeloma therapies.
• In June 2021, MEDIPOST announced that the company has expanded the production facilities for its knee osteoarthritis stem cell products, CARTISTEM and SMUP-IA-01, and will start preparing for GMP (Good Manufacturing Practice) certification.
• In September 2022, Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. and will focus primarily on advancing its CendR Platform technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs.
• In March 2019, BioTime, Inc acquired Asterias Biotherapeutics, Inc. which deals in regenerative medicines to consolidate its stem cell therapies product portfolio.

Company Profiles

• MEDIPOST
• Pharmicell Co., Inc.
• RichSource
• BioTime, Inc.
• Mesoblast Limited
• Holostem Terapie Avanzate Srl
• U.S. Stem Cell, Inc.
• Caladrius Biosciences, Inc.
• TiGenix NV
• AlloSource